KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

Novavax (NVAX) Accumulated Depreciation & Amortization (2016 - 2025)

Novavax has reported Accumulated Depreciation & Amortization over the past 16 years, most recently at $28.0 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $28.0 million for Q4 2025, down 41.67% from a year ago — trailing twelve months through Dec 2025 was $28.0 million (down 41.67% YoY), and the annual figure for FY2025 was $28.0 million, down 41.67%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $28.0 million at Novavax, down from $48.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for NVAX hit a ceiling of $48.0 million in Q4 2024 and a floor of $13.0 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $29.0 million (2022), compared with a mean of $31.8 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 202.33% in 2021 and later crashed 41.67% in 2025.
  • Novavax's Accumulated Depreciation & Amortization stood at $13.0 million in 2021, then surged by 123.08% to $29.0 million in 2022, then skyrocketed by 41.38% to $41.0 million in 2023, then rose by 17.07% to $48.0 million in 2024, then tumbled by 41.67% to $28.0 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $28.0 million (Q4 2025), $48.0 million (Q4 2024), and $41.0 million (Q4 2023) per Business Quant data.